Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-26 14:30 |
Kommuniké från årsstämma den 26 maj 2023 i Alligator Bioscience AB
|
Swedish | 69.2 KB | ||
| 2023-05-26 14:30 |
Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2…
|
English | 69.9 KB | ||
| 2023-05-24 19:30 |
Alligators offentliggör tilläggsprospekt
|
Swedish | 72.5 KB | ||
| 2023-05-24 19:30 |
Alligator publishes supplementary prospectus
|
English | 71.7 KB | ||
| 2023-05-18 12:30 |
Alligator Bioscience erhåller särläkemedelsklassificering från FDA för mitazali…
|
Swedish | 68.2 KB | ||
| 2023-05-18 12:30 |
Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pa…
|
English | 65.0 KB | ||
| 2023-05-12 20:15 |
Alligator announces preliminary outcome of rights issue
|
English | 73.2 KB | ||
| 2023-05-12 20:15 |
Alligator offentliggör preliminärt utfall i företrädesemission
|
Swedish | 73.1 KB | ||
| 2023-05-11 14:15 |
Alligator Bioscience and Orion Corporation announce exercise of development opt…
|
English | 67.3 KB | ||
| 2023-05-11 14:15 |
Alligator Bioscience och Orion Corporation meddelar att utvecklingsmöjlighet ny…
|
Swedish | 67.9 KB | ||
| 2023-05-09 17:30 |
Alligator publishes supplementary prospectus
|
English | 73.4 KB | ||
| 2023-05-09 17:30 |
Alligators offentliggör tilläggsprospekt
|
Swedish | 72.8 KB | ||
| 2023-04-26 16:30 |
Alligator Bioscience publishes prospectus in connection with forthcoming rights…
|
English | 79.1 KB | ||
| 2023-04-26 16:30 |
Alligator Bioscience offentliggör prospekt med anledning av förestående företrä…
|
Swedish | 78.4 KB | ||
| 2023-04-25 08:00 | Swedish | 1.7 MB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
